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Induction of renoprotective genes by cobalt ameliorates tubu-
lointerstitial injury in the progressive Thy1 nephritis model.
Background. We previously demonstrated that chronic hy-
poxia has pivotal roles in the progression of tubulointersti-
tial injury from the early stage of the uninephrectomized
Thy1 nephritis model. We have also shown that pretreatment
of cobalt confers renoprotection in the ischemia/reperfusion
(I/R) injury, in association with the up-regulation of hypoxia-
inducible factor (HIF)–regulated genes. Here, we tested the
hypothesis that cobalt administration not only attenuates acute
ischemic insult, but also ameliorates tubulointerstitial injury
secondary to chronic hypoxia.
Methods. We applied sustained cobalt treatment to the
uninephrectomized Thy1 nephritis model at 3 to 5 weeks,
when tubular hypoxia appeared. Histologic evaluation, includ-
ing glomerular and peritubular capillary networks, was made
at 8 weeks. HIF activation was confirmed by real-time poly-
merase chain reaction (PCR) analyses for HIF-regulated genes,
such as erythropoietin (EPO), vascular endothelial growth fac-
tor (VEGF), and heme oxygenase 1 (HO-1). Up-regulation of
HIF-1a and HIF-regulated genes was also verified by West-
ern blotting analysis. To elucidate responsible mechanisms of
cobalt in the amelioration of tubuloniterstitial injury, termi-
nal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine
triphosphate (dUTP) nick end labeling (TUNEL) staining was
conducted at 5 weeks. A combination therapy with angiotensin
receptor blocker (ARB), olmesartan, was also challenged.
Results. Although the intervention did not change glomerular
structural damage or urinary protein excretion rate, tubuloin-
terstitial injury was improved in cobalt-treated animals when
compared with the vehicle-treated group. The amelioration
was associated with the parallel up-regulation of renoprotec-
tive, HIF-regulated gene expression. TUNEL staining revealed
that the number of apoptotic cells was reduced in the cortex
by cobalt administration, suggesting that renoprotection was
achieved partly through its antiapoptotic properties. Further-
more, it was demonstrated that cobalt treatment exerts addi-
tional renoprotective effects with the ARB treatment in this
model.
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Conclusion. Maneuvers to activate HIF in the ischemic tubu-
lointerstitium will be a new direction to future therapeutic
strategies.
Recent reports emphasize chronic hypoxia in the tubu-
lointerstitium as a mechanism of progression in a number
of renal diseases [1–6]. Histologic studies of human kid-
neys and animal models have shown that extensive tubu-
lointerstitial injury is associated with loss of peritubular
capillaries, implying that chronic hypoxia due to loss of
micovasculature plays pivotal roles in the progression of
tubulointerstitial injury [7–10].
In addition to peritubular capillary loss, chronic hy-
poxia in the tubulointerstitium can occur via several
mechanisms. Previous studies from our group demon-
strated a decrease in blood flow of peritubular capillar-
ies, and hypoxia thereof, prior to the development of
structural tubular and capillary damage in two distinct
glomerulopathies. In the remnant kidney, hypoxia was
associated with the narrowing of peritubular capillaries
and treatment of angiotensin receptor blocker (ARB) re-
stored blood flow with improvement of subsequent oxy-
genation in the kidney [11]. These findings suggested that
changes in peritubular capillaries may be secondary to
outflow constriction of the glomerular capillary bed by
angiotensin II (Ang II). We also observed tubulointersti-
tial hypoxia alongside with decreased capillary blood flow
in a model of accelerated glomerulosclerosis induced by
repeated injections of anti-Thy1 antibody in uninephrec-
tomized rats [12]. These findings indicated that blood flow
of peritubular capillaries can be affected by the glomeru-
lar capillary networks and efferent arterioles, and the
stagnant peritubular perfusion in turn leads to tubuloin-
terstitial hypoxia in the early-phase of glomerulopathies,
thus establishing a more solid basis on the role of hypoxia
in the progression of renal diseases.
Given that renal hypoxia has pivotal roles not only on
the progression to renal failure but on the early develop-
ment of tubulointerstitial injury, chronic hypoxia could be
a valid therapeutic target for renal diseases. To this end,
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an endogenous mechanism to cope with hypoxia was in-
vestigated. Hypoxia-inducible factor (HIF), composed of
a and b subunits, is a master regulator of genes activated
by low oxygen tension. In normoxia, the HIF-a subunit is
ubiquitinated and degraded by proteasomes. The oxygen-
sensing pathway involves the oxygen-dependent prolyl
hydroxylation of HIF-1a by prolyl-4-hydroxylase [13, 14],
which serves as a signal for polyubiquitination and pro-
teasomal degradation [15, 16]. And cobalt is known to
cause accumulation of HIF-a protein within the cells and
induce HIF-mediated transcription by inhibiting prolyl
hydroxylation of the a subunit [17].
We recently demonstrated renoprotective effects of
cobalt in the ischemic acute renal failure [18]. Admin-
istration of cobalt led to the induction of HIF-regulated
genes, such as vascular endothelial growth factor (VEGF)
and erythropoietin (EPO), and improved tubulointer-
stitial damage in this model. Substantial in the acute
ischemic injury, however, it remained to be elucidated
whether it could also be applied to chronic, progres-
sive disease models in which hypoxia takes on certain
roles. Here, we tested whether cobalt attenuates tubuloin-
terstitial injury secondary to chronic hypoxia, using the
uninephrectomized Thy1 nephritis model. Our findings
indicated that activation of HIF by cobalt exerts renopro-
tective roles in the ischemic tubulointerstitium, partly via
suppression of apoptosis, while the density of peritubular
capillaries was unaffected. Furthermore, this method had
additive, positive effects to the standard antiproteinuric
therapy, namely, the blockade of the renin-angiotensin
system (RAS) in the hypoxic tubulointerstitium. Combi-
nation therapy suggested a potential synergistic renopro-
tection in this disease model.
METHODS
Experimental protocol
All experiments were conducted in accordance with
the Guide for Animal Experimentation, at the Faculty of
Medicine, University of Tokyo, Japan. Six-week-old male
Srague-Dawley rats (Nippon Seibutsu Zairyo Center Co.,
Ltd., Saitama, Japan) weighing 160 to 200 g received re-
peated intravenous injections of IgG (OX-7) mouse mon-
oclonal anti-Thy1.1 antibody (1.2 mg/kg body weight)
(N = 32) or vehicle (control) (N = 8), at 1 and 2 weeks
(week −1 and week 0) after right nephrectomy (week
−2). Rats were housed in metabolic cages for overnight
collection of urine, and blood samples were obtained via
tail vein for the evaluation of renal functions. After col-
lection of urine at 1 week, nephrectomized, Thy1-injected
rats were administrated with cobalt chloride (Thy1 cobalt
group 2.7 mg/kg, subcutaneously, once every 3 days) (N =
17) or vehicle (Thy1 group) (N = 15) for 3 weeks. The
starting time point of cobalt treatment was determined
based on our previous findings that tubulointerstitial hy-
poxia was evident at this time point [12]. The dose and pe-
riod of cobalt treatment were determined to minimize the
loss of body weight, according to preliminary studies. At
the end of cobalt administration, 5 weeks, kidneys were
obtained for reverse transcription-polymerase chain re-
action (RT-PCR) analysis and terminal deoxynucleotidyl
transferase (TdT)-mediated deoxyuridine triphosphate
(dUTP) nick end labeling (TUNEL) staining (control) (N
= 2), Thy1 (N = 7), and Thy1 cobalt (N = 9). Remaining
animals were sacrificed at 8 weeks for tissue analysis.
A second set of experiments were conducted to see
if cobalt treatment exhibits additive effects to the ARB
treatment. Additional rats were assigned to either (1)
Thy1 (N = 4), (2) Thy1 + ARB (N = 7), or (3)
Thy1 + ARB + cobalt (N = 7) groups. For the ARB
treatment groups, 10 mg/kg body weight of olmesartan
(Pharmacology and Molecular Biology Research Labo-
ratories, Sankyo Pharmaceuticals, Tokyo, Japan) was ad-
ministered via gastric gavage (1 mg/mL in 0.5% sodium
carboxymethylcellulose) at 2 to 5 weeks, 5 times a week.
In a third set of experiments, the relative contributory
role of VEGF on cobalt-mediated renoprotection was
investigated using anti-VEGF neutralizing antibody, as
previously reported [19]. Rats were administered with
anti-VEGF neutralizing antibody (4 lg/head intraperi-
toneally, 12 hours prior to injection of cobalt) (R&D
Systems, Minneapolis, MN, USA) or control IgG, dur-
ing weeks 2 through 5 (N = 6 in each group). These rats
were euthanized for evaluation at weeks 5 and 8. Inhibi-
tion of circulating VEGF in control rats led to minimal
pathologic effects [20] (not shown).
Renal histologic analyses
Tissues were fixed in methyl-Carnoy’s solution
and paraffin-embedded. Three micrometer sections
were stained with the periodic acid-Schiff (PAS)
reagent and counterstained with hematoxylin. An in-
direct immunoperoxidase method was used to iden-
tify the following antigens; monocytes/macrophages with
murine monoclonal IgG1 antibody endothelin-1 (ED-1)
(Chemicon, Temecula, CA, USA); vimentin with murine
monoclonal IgG antibody V9 (Dako, Carpinteria, CA,
USA); and aminopeptidase P of microvascular endothe-
lial cells with murine monoclonal IgG1 antibody JG-
12 [21] (Bender MedSystems, San Bruno, CA, USA).
Formalin-fixed and paraffin-embedded tissue was sec-
tioned at 6 lm, for the assessment of TUNEL staining,
using a commercial apoptosis detection kit (TACS2 TdT-
Blue Label In Situ Apoptosis Detection Kit) (Trevigen,
Gaithersburg, MD, USA).
Semiquantitative analyses of renal histologic feature
Quantification was performed in a blinded manner
using 30 randomly selected glomeruli or more than
15 randomly selected fields of cortex per cross-section.
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Glomerulosclerosis, defined as synechiae formation by
PAS staining with focal or global obliteration of capillary
loops, was graded as follows: 0, normal; 1, 0% to 25% of
glomerular area was affected; 2, 25% to 50% affected;
3, 50% to 75% affected; and 4, 75% to 100% affected
[22]. Tubulointerstitial injury was graded (0 to 5+) on
the basis of the percentage of tubular cellularity, base-
ment membrane thickening, cell infiltration, dilatation,
atrophy, sloughing, or interstitial widening as follows: 0,
no change; 1, <10% tubulointerstitial injury; 2, 10% to
25%; 3, 25% to 50%; 4, 50% to 75%; and 5, 75% to 100%
[23, 24]. Tubules that were vimentin-positive or were sur-
rounded by vimentin-positive cells, ED-1–positive cells
and apoptotic (TUNEL-positive) cells were counted in
20 randomly selected cortical fields with ×20 objective.
Semiquantitative analyses of glomerular or peritubular
capillary loss
Glomerular or peritubular capillary loss was assessed
by immunostaining for renal microvascular endothelium
with JG-12 antibody. Loss of glomerular capillary loops
was graded as follows: 0, no negative glomerular tuft
staining for endothelium; 1, 1% to 25% of glomerular
tuft negative for endothelium; 2, 25% to 50% negative; 3,
50% to 75% negative; and 4, 75% to 100% negative [25].
Peritubular capillary loss was analyzed using rarefaction
index, which is percentage area with no capillaries identi-
fied with JG-12 antibody and represents the sparseness of
peritubular capillaries, as reported previously [7]. Briefly,
it was determined by counting the numbers of squares in
10 × 10 grids that did not contain JG-12–positive per-
itubular capillary staining, in at least 10 nonoverlapping
sequential fields, at ×200 magnification. The minimal pos-
sible capillary rarefaction index is 0 (i.e., every square in
the grid contains a JG-12–positive peritubular capillary),
whereas the maximal score is 100 (i.e., JG-12–positive
peritubular capillaries are absent from every square in
the grid).
Real-time quantitative PCR analyses
Total RNA was extracted from kidney homogenates
with Isogen (Nippon Gene, Tokyo, Japan). To synthesize
cDNA from total RNA, SuperScript II Reverse Tran-
scriptase was used (Life Technologies BRL, Rockville,
MD, USA). Renal mRNA levels were assessed by real-
time quantitative PCR using SYBR Green PCR reagent
(Qiagen, Hilden, Germany) and iCycler PCR system
(Bio-Rad Laboratories, Hercules, CA, USA) according
to manufacturer’s instructions. Briefly, amplification re-
actions consisted of 1 lL of cDNA, 12.5 lL of the Univer-
sal 2× PCR MasterMix (Qiagen), and 5 lL each of the
specific primers. Primer concentrations in the final vol-
ume of 25 lL were 500 nmol/L. In control experiments
with triplicates, no false positives were detected and the
variance between each of the replicates was within 5%.
All PCR reactions were performed in triplicate. Ct, or
threshold cycle, was used for relative quantification of
the input target number. The amount of Ct for control
samples was considered 1 (i.e., 2◦). The number of Cts
for other samples were subtracted by cycles of control
samples and recorded as Ct. The relative amount of
amplified genes is given by 2−Ct. The mRNA levels of
target genes were normalized to levels of b-actin. PCR
primers for heme oxygenase (HO-1), VEGF, and EPO
have been described previously [18].
Immunoblotting
The induction of the a subunit of HIF-1 and its regu-
lated genes were verified by Western blotting. Proteins
were extracted from renal cortex of either vehicle- or
cobalt-treated rats. Aliquots were separated by 7.5%
(HIF-1a), 10% [glucose transporter 1 (GLUT1)] or
15% VEGF sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions
and transferred onto polyvinylidine difluoride (PVDF)
membranes (Millipore, Tokyo, Japan). Specific bands
were detected with anti-HIF-1a (Novus Biologicals,
Littleton, CO, USA), anti-GLUT1 (Chemicon) and
anti-VEGF (Santa-Cruz Biochemistry, Santa Cruz, CA,
USA) antibodies followed by incubation with alkaline
phosphatase (AP)–conjugated secondary antibodies.
Nitroblue tetrazolium chloride/5-bromo-4-chloro-3-
indolyl-phosphate (NBT/BCIP) (Sigma Chemical Co.,
St. Louis, MO, USA) was used as substrate.
Statistical analysis
Data were reported as mean ± SE. Statistical analy-
ses were performed using the t test. Nonparametric data
were analyzed with the Mann-Whitney test when appro-
priate. Differences with P values of < 0.05 were consid-
ered significant.
RESULTS
Global features
First, the feasibility of cobalt for long-term use was es-
timated by measuring physical and biochemical parame-
ters. After 3 weeks of cobalt injection to control rats, there
were no significant changes in terms of body weight (ve-
hicle, 447 ± 18 g; cobalt, 434 ± 39 g), systolic blood pres-
sure (vehicle, 116 ± 9 mm Hg; cobalt, 114 ± 20 mm Hg),
urinary protein excretion (vehicle, 13.1 ± 3.1 mg/day/kg;
cobalt, 12.1 ± 2.2 mg/day/kg), and blood urea nitrogen
(BUN) levels (vehicle, 17.2 ± 4.9 mg/dL; cobalt, 18.6 ±
0.9 mg/dL).
In the Thy1 and Thy1 cobalt groups, urinary protein
excretion at 1 week, that is, before cobalt treatment, was
similar (120.1 ± 26.2 mg/day/kg body weight vs. 131.3 ±
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Fig. 1. Temporal profile of renal function and body weight. (A) Urinary protein excretion levels in the Thy1 group increased significantly as
compared with controls, which were not altered by cobalt administration. (B) Cobalt injection did not affect the body weight in both control and
Thy1 rats.
Fig. 2. Glomerular injury was not improved
by cobalt administration. In the control and
control cobalt groups, glomerular structure
remained intact (A and B). Periodic acid-
Schiff (PAS) staining of the Thy1 (C) and
Thy1 cobalt (D) groups showed that glomeru-
lar sclerosis, defined by synechiae formation,
developed to a similar degree (magnification,
×400).
18.9 mg/day/kg body weight) (P = NS). After the cobalt
administration period, urinary protein of both groups in-
creased in a similar manner. Cobalt injection did not af-
fect increases in body weight (Fig. 1).
Cobalt administration did not prevent progression to the
irreversible glomerulosclerosis
Glomerular morphology was evaluated to see the
potential effect of cobalt on glomerular injury. Glomeru-
lar injury, which was defined according to synechiae for-
mation by PAS staining with focal or global obliteration
of capillary loops, developed to a similar degree in both
Thy1 and Thy1 cobalt groups, at 8weeks (glomerular in-
jury score control, 0.26 ± 0.08; Thy1, 2.69 ± 0.21; and Thy1
cobalt, 2.23 ± 0.22) (Fig. 2). Glomerular capillary loss, de-
fined as the decreased staining with JG-12 antibody, was
similarly observed in both groups (control, 0.06 ± 0.03;
Thy1, 1.87 ± 0.30; and Thy1 cobalt, 1.92 ± 0.15), sug-
gesting no protective effect of cobalt against glomerular
injury in this model.
Cobalt administration improved tubulointerstitial injury
in the uninephrectomized Thy1 nephritis model
Previously we demonstrated that chronic hypoxia un-
derlies the progression of tubulointerstitial injury in the
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Table 1. Glomerular and tubulointerstitial (TI) injury among study groups
Glomerular injury Tubulointerstitial injury
Glomerular injury (PAS) Capillary loss score (JG = 12) TI injury score (PAS) Rare faction index (JG = 12)
Control 0.26 ± 0.08 0.06 ± 0.03 0.27 ± 0.08 4.54 ± 0.22
Thy1 2.69 ± 0.21a 1.87 ± 0.30a 2.28 ± 0.32a 11.15 ± 0.55a
Thy1 cobalt 2.23 ± 0.22a 1.92 ± 0.15a 1.33 ± 0.16a,b 11.74 ± 0.63a
PAS is periodic acid-Schiff.
aP < 0.01 vs. control.
bP < 0.05 vs. Thy1 group.
uninephrectomized Thy1 nephritis model, providing the
rationale for testing the hypothesis that sustained low-
dose cobalt treatment could remit chronic, progressive
renal diseases through activation of HIF. For this purpose,
we administered cobalt from the end of 1 week up until
5 weeks, when chronic hypoxia was observed in this dis-
ease model [12]. Tubulointerstitial injury developed in a
diffuse manner in the Thy1 group, which was improved in
the Thy1 cobalt group (tubulointerstitial injury score con-
trol, 0.27 ± 0.08; Thy1, 2.28 ± 0.32; and Thy1 cobalt, 1.33
± 0.16; and Thy1 versus Thy1 cobalt P < 0.05, data sum-
marized in Table 1). Moreover, expression of vimentin
in tubular cells or in cells surrounding tubules was obvi-
ously increased in the Thy1 group, which was decreased
by cobalt administration (vimentin-positive tubules per
field control, 1.81 ± 0.78; Thy1, 22.0 ± 2.53; Thy1 cobalt,
7.73±2.93; and Thy1 versus Thy1 cobalt P <0.01) (Fig. 3).
Macrophage infiltration in the tubulointerstitium, as de-
termined by the number of ED-1–positive cells, was also
reduced in rats treated with cobalt (ED-1–positive cells
per field control, 14.7 ± 2.63; Thy1, 25.6 ± 2.87; Thy1
cobalt, 17.3 ± 2.21; and Thy1 versus Thy1 cobalt P <
0.05).
Cobalt chloride–induced expression of renoprotective,
HIF-regulated genes
To investigate the possible contribution of renoprotec-
tive genes induced by cobalt, we performed real-time
quantitative PCR analysis using kidneys obtained after
repeated cobalt injections. Relative quantification was
based on the difference in Ct of target and control samples
( = Ct) in cobalt-treated and control groups, respec-
tively. Although mild increases in HO-1, VEGF, and EPO
mRNA were observed in the Thy1 group, cobalt admin-
istration induced much higher expression. Fold increases
of each mRNA expression in this group were 11.2-, 10.2-,
and 11.0-fold, for HO-1, VEGF, and EPO, respectively
(Fig. 4A).
The up-regulation of HIF-1a and HIF-regulated genes
were also verified at the protein level (Fig. 4B and C). The
specific band corresponding to HIF-1a appeared in the
cobalt group, while absent in the vehicle-treated group.
Similarly, GLUT1 and VEGF, two of the representative
target genes of HIF-1, were significantly up-regulated by
cobalt, making it more likely that the dosage of cobalt
we employed here successfully activated HIF and HIF-
regulated genes.
Cobalt administration did not prevent peritubular
capillary loss
Influence of cobalt administration on peritubular
capillary density was of particular interest, because a
considerable increase of VEGF was observed in cobalt-
treated kidneys. In the Thy1 group, peritubular capillary
density was decreased at 8 weeks as compared with the
control group. Cobalt treatment, however, failed to pre-
vent the decline of peritubular capillary density (rarefac-
tion index control, 4.54 ± 0.22; Thy1, 11.15 ± 0.55; and
Thy1 cobalt, 11.74 ± 0.63%).
Cobalt reduced the number of TUNEL-positive,
apoptotic cells in the tubulointerstitium
To further elucidate mechanisms by which cobalt
administration ameliorated tubulointerstitial injury, we
conducted TUNEL staining to count the number of apop-
totic cells. In the Thy1 group, TUNEL-positive, apoptotic
cells increased in tubular epithelium and interstitial com-
partments at 5 weeks, while significantly decreased by the
administration of cobalt (TUNEL-positive cell number
per field control, 0.41 ± 0.03; Thy1, 4.78 ± 0.97; and Thy1
cobalt, 2.52 ± 0.58) (P < 0.01), implying antiapoptotic
properties of this regimen (Fig. 5).
Activation of HIF by cobalt affords synergistic protection
with the RAS blockade in the ischemic tubulointerstitium
Looking back on the aforementioned results that
cobalt treatment conferred renoprotection in terms of
tubulointerstitial injury, we plotted the correlation be-
tween proteinuria and tubulointerstitial injury in each
individual rat of Thy1 and Thy1 cobalt groups (Fig. 6).
In the cobalt-treated group, the y axis of the regression
line shifted downward as compared with that of the Thy1
group, indicating the partial remission of tubulointersti-
tial injury by this method, although the damage was still
remaining depending on the degree of proteinuria. In this
regard, we conducted a second set of experiments to ad-
dress whether cobalt works synergistically with the stan-
dard antiproteinuric therapy, the blockade of RAS.
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Fig. 3. Effect of cobalt administration on
tubulointerstitial injury. Periodic acid-Schiff
(PAS) staining revealed significant tubuloint-
erstitial injury at 8 weeks in the uninephrec-
tomized Thy1 nephritis (C), which was
improved in the Thy1 cobalt group (D).
Vimentin-positive tubules in the Thy1 group
(G) were reduced in number in the Thy1
cobalt kidneys (H). Cobalt treatment alone
did not induce any recognizable morphologi-
cal changes in control kidneys (A) vs. (B) and
(E) vs. (F) (magnification, ×200).
Proteinuria was reduced from 175.2 ± 56.8 mg/day/kg
to 73.5 ± 27.1 mg/day/kg (Thy1 ARB) and 85.4 ± 37.3 mg/
day/kg (Thy1 ARB + cobalt) at the end of adminis-
tration period of ARB. As summarized in Table 2, a
consistent, synergistic protection was observed in the
tubulointerstitium, albeit seemingly independent of al-
terations in microvasculature (tubulointerstitial injury
score Thy1, 2.91 ± 0.37; Thy1 ARB, 1.71 ± 0.19; Thy1
ARB + cobalt, 1.38 ± 0.21; and Thy1 ARB versus Thy1
ARB + cobalt P= 0.02) (rarefaction index Thy1, 14.16 ±
0.41; Thy1 ARB, 11.91 ± 0.60; and Thy1 ARB + cobalt,
11.98 ± 1.21). Glomerular injuries were again unaffected
by cobalt treatment, both in terms of glomerular sclero-
sis score and of capillary loss score (glomerular injury
score Thy1, 2.45 ± 0.11; Thy1 ARB, 1.99 ± 0.21; and
Thy1 ARB + cobalt, 1.90 ± 0.23) (glomerular capillary
loss score Thy1, 1.90 ± 0.22; Thy1 ARB, 1.39 ± 0.23; and
Thy1 ARB + cobalt, 1.52 ± 0.25). Responsible mecha-
nisms underlying synergistic renoportection were investi-
gated by vimentin and TUNEL staining (Fig. 7). Additive,
positive effects of cobalt were ascribed to its properties
to suppress dedifferentiation and apoptosis of affected
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Fig. 4. Cobalt chloride induced the expression of hypoxia-inducible
factor (HIF)-associated, renoprotective genes. Expression of mRNA
for each gene in the whole kidney of control, Thy1, and Thy1 cobalt
groups (N = 2, 3, and 3, respectively) at 5weeks (A). mRNA expres-
sion was determined by real-time quantitative reverse transcription-
polymerase chain reaction (RT-PCR). Expression was normalized to
the housekeeping b-actin gene and was shown as a ratio to control
animals. One percent of the total cDNA was analyzed in triplicate;
comparative controls without RT were negative for each gene. Western
blotting analysis shows successful up-regulation of HIF-1a (B), glucose
transporter 1 (GLUT1) and a 21 kD fragment (p21) of vascular en-
dothelial growth factor (VEGF) (C), at the protein level. HO-1 is heme
oxygenase 1; EPO is erythropoietin.
renal tubules, although the latter did not reach statisti-
cal significance (vimentin-positive tubules per field Thy1,
23.0±1.6; Thy1 ARB, 16.4±3.0; and Thy1 ARB+ cobalt,
10.4 ± 2.2; and Thy1 ARB versus Thy1 ARB + cobalt,
P < 0.01) (TUNEL-positive cell number per field Thy1,
4.33 ± 0.71; Thy1 ARB, 2.71 ± 0.62; and Thy1 ARB +
cobalt, 2.16 ± 0.51; and Thy1 ARB versus Thy1 ARB +
cobalt, P= 0.09).
Blockade of circulating VEGF partially offsets
the beneficial effect of cobalt
Finally, we attempted to estimate the relative con-
tribution of VEGF in cobalt-mediated renoprotection.
Cobalt-treated, uninephrectomized Thy1 rats were ad-
ministered with either control IgG (Thy1 cobalt + IgG) or
anti-VEGF neutralizing antibody (Thy1 cobalt + VEGF
neutralizing antibody). The numbers of vimentin-positive
tubules and TUNEL-positive cells were moderately in-
creased in the latter group. Similarly, PAS examination
at 8 weeks revealed partial, but significant, reversal of
cobalt-mediated histologic improvement by this method
(Table 3).
A proposed diagram of our current study is sum-
marized in Figure 8. Induction of HIF-regulated genes
by cobalt protects ischemic tubulointerstitium in this
model, partly by inhibiting tubular cell apoptosis. And,
when combined with the antiproteinuric therapy, it more
strongly attenuates tubulointerstitial injury.
DISCUSSION
We previously demonstrated that cobalt pretreatment
protects kidneys against acute ischemic insult, suggest-
ing beneficial roles of cobalt, and activation of HIF, in
protecting tissues from hypoxia [18]. This study was un-
dertaken to address whether this strategy also applies to
chronic renal diseases in which hypoxia exists and plays
certain roles in their progression. Cobalt administration
was started at the end of 1 week, when decline of oxygen
tension in cortical tubules occurred in the uninephrec-
tomized Thy1 nephritis model [12].
In vivo activation of HIF was accomplished by ad-
ministering cobalt to rats. In normoxia, HIF-a protein
is quickly degraded through ubiquitin-proteasomal path-
ways, which is triggered by prolyl hydroxylation, and the
enzymatic activity of prolyl hydroxylases depends on iron
as the activating metal, 2-oxoglutarate as a cosubstrate
and ascorbic acid as a cofactor. Cobalt has been suggested
to induce the “hypoxia-mimetic” effect via its ability to
substitute for iron [17], and by depleting intracellular
ascorbate [26]. Although the mechanisms appear to be
multifaceted, cobalt administration to rats led to success-
ful activation of HIF and induction of its associated genes,
which we confirmed by real-time PCR and immunoblot-
ting of HIF target genes.
Repeated injections of anti-Thy1 antibody after
uninephrectomy directly injured mesangial cells and led
to irreversible structural damage in glomeruli [12]. The
glomerular lesion and glomerular capillary loss were not
improved by cobalt treatment. This was not surprising
because primary mediators of glomerular injury in this
model are complement-mediated mesangial injury and
subsequent release of cytokines and growth factors [27,
28]. Structural glomerular damage may have reached the
threshold not to be overcome by the up-regulation of
HIF-regulated, renoprotective genes. This would also ex-
plain similar degrees of proteinuria observed in the Thy1
and Thy1 cobalt groups.
On the other hand, tubulointerstitial injury was clearly
improved by cobalt administration, in association with
the induction of HIF-regulated, renoprotective genes
such as EPO, HO-1, and VEGF. The first place we looked
for was the vascular network of glomerular and peritubu-
lar capillaries, because HIF stimulates the expression of
a number of target genes essential for angiogenesis. In
Tanaka et al: Cobalt ameliorated tubulointerstitial injury 2721
Fig. 5. Detection of apoptosis by terminal
deoxynucleotidyl transferase (TdT)-
mediated deoxyuridine triphosphate (dUTP)
nick end labeling (TUNEL) staining. In the
Thy1 group, TUNEL-positive, apoptotic
cells increased in tubular epithelium and
the interstitial compartment at 5 weeks (C),
which was decreased in the Thy1 cobalt group
(D). Minimal positive cells were observed in
the control (A) and control cobalt (B) groups
(magnification, ×200).
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Fig. 6. Correlation between urinary protein
excretion and tubulointerstitial injury. Corre-
lations between proteinuria and tubulointer-
stitial injury were plotted with each individual
rat in both Thy1 and Thy1 cobalt groups. The
decrease in the y axis in the Thy1 cobalt group
indicates that cobalt administration attenu-
ated tubulointerstitial injury, although the in-
jury was remaining substantially, depending
on the degree of proteinuria developed in
each individual rat. There was a positive cor-
relation between proteinuria and tubulointer-
stitial injury in both groups (Thy1, y = 0.0056x
+ 1.3663, R2 = 0.71; Thy1 cobalt, y = 0.0063x
+ 0.8742, R2 = 0.72).
Table 2. Administration of cobalt worked synorgistically with the angiotensin receptor blocker (ARB) treatment against ischemic
tubulointerstitial (TI) injury
Glomerular injury Tubulointerstitial injury
Glomerular sclerosis (PAS) Capillary loss score (JG-12) TI injury score (PAS) Rare faction index (JG-12)
Thy1 (vehicle) 2.45 ± 0.11 1.90 ± 0.22 2.91 ± 0.37 14.16 ± 0.41
Thy1 ARB 1.99 ± 0.21a 1.39 ± 0.23a 1.71 ± 0.19a 11.91 ± 0.60a
Thy1 ARB + cobalt 0.90 ± 0.23a 1.52 ± 0.25c 1.38 ± 0.21a,b 11.98 ± 1.21a
PAS is periodic acid-Schiff.
aP < 0.01 vs. vehicle.
bP < 0.05 vs. Thy-ARB group.
cP < 0.05 vs. vehicle.
addition, evidence has been accumulating that tubuloin-
terstitial injury is associated with the loss of peritubu-
lar capillaries, and therapies targeting angiogenesis and
the maintenance of microvasculature successfully retards
the progression of renal diseases [29–31]. In this study,
however, the density of peritubular capillaries was not
improved in the Thy1 cobalt group, despite the marked
induction of VEGF mRNA and protein by this method.
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Fig. 7. Cobalt treatment protected renal tubules from dedifferentiation and apoptosis synergistically with ARB. Administration of cobalt in
combination with angiotensin receptor blocker (ARB) synergistically reduced the number of vimentin-positive tubular cells (A) and terminal
deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL)-positive, apoptotic cells (B). The
numbers of vimentin-/TUNEL- positive cells decreased from 23.03 ± 0.63/4.33 ± 0.71 to 16.41 ± 3.04/2.71 ± 0.61 by ARB treatment (P < 0.01
each), with further reduction to 10.42 ± 2.17/2.16 ± 0.51 by the additional cobalt treatment (P < 0.01 and P= 0.09, respectively) [counting per ×200
field N = 5 (Thy1), N = 7 (Thy1 ARB), N = 7 (Thy1 ARB + cobalt). ∗∗P < 0.01 vs. Thy1 group].
Table 3. Effect of anti-vascular endothelial growth factor (VEGF) nutralizing antibody in the cobalt-treated rats
Tubulointerstitial Vimentin-positive TUNEL-positive
score (PAS) tubules (per field) cells (per field)
Thy1 (vehicle) 2.25 ± 0.15 18.6 ± 1.76 4.60 ± 0.57
Thy1 cobalt + IgG 1.13 ± 0.10a 6.53 ± 0.48b 2.87 ± 0.86b
Thy1 cobalt + VEGF nutralizing antibody 1.70 ± 0.13b,c 13.5 ± 2.83 3.76 ± 0.70
P value vs. control IgG (P = 0.01) (P = 0.09) (P = 0.07)
Abbreviations are: PAS, Periodic acid–Schiff; TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling.
aP < 0.01 vs. Thy1.
bP < 0.05 vs. Thy1.
cP < 0.05 vs. Thy cobalt + IgG group.
In an effort to elucidate other mechanisms likely respon-
sible for the amelioration of tubulointerstitial injury by
cobalt, we carried out TUNEL staining and clarified that
the number of apoptotic cells was significantly reduced
by cobalt. These results confirmed and extended previ-
ous observations that apoptosis plays an important role
in hypoxia-mediated kidney injury [32–35].
EPO, one of the up-regulated genes in the current
study, has been emphasized to exhibit antiapoptotic
effects through activation of signaling pathways down-
stream of the EPO receptor in various tissues, includ-
ing brain, spinal cord, retina, testis, and the kidney. In
vivo, therapeutically applied EPO has been shown to re-
duce the infarct volume in various stroke animal mod-
els, to prevent retinal degeneration, and to ameliorate
spinal cord injury [36]. Parsa et al [37] reported that EPO
treatment improved cardiac function following myocar-
dial infarction, which was associated with mitigation of
myocyte apoptosis. In the kidney, exogenous administra-
tion of EPO has been shown to protect tubular cells from
injury in the ischemia/reperfusion (I/R) model [38, 39].
Although we have not investigated responsible mecha-
nisms for the reduced number of apoptosis, local EPO
production might have contributed to the alleviation of
tubulointerstitial injury by cobalt treatment.
HO-1, an enzyme responsible for catalysis of heme to
iron, carbon monoxide (CO), biliverdin, and bilirubin,
has been shown to inhibit apoptosis in various cell types
such as endothelial cells, fibroblasts, and neuronal cells
[40–42]. In kidneys, recent studies have suggested that
HO-1 confers resistance to apoptosis and exerts reno-
protective roles [43, 44]. We speculate that similar mech-
anisms also participate in the histologic improvement
observed in this study.
In the current study, contribution of VEGF to the main-
tenance of microvasculature was not observed. Nonethe-
less, it should be emphasized that the blockade of
circulating VEGF in cobalt-treated rats resulted in par-
tial reversal of histologic improvement, as determined by
TUNEL, vimentin, and PAS staining. This is important
for the following reasons. First, in spite of several lines of
studies showing positive effects of VEGF, the role of it in
nephrology in general is still under debate and needs to
be verified according to each pathologic context. Second,
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Fig. 8. Proposed diagram of our study. A summarized diagram out of
this study is shown. Cobalt stimulates hypoxia-inducible factor (HIF)-
regulated gene expression and protects ischemic tubulointerstitium in
this model, partly via suppression of tubular cell apoptosis. By blocking
proteinuria simultaneously, this strategy exerts more effective renopro-
tection (see text for details). Abbreviations are: NX, nephrectomy; HO-
1, heme oxygenase 1; EPO, erythropoietin; VEGF, vascular endothelial
growth factor.
blocking of VEGF alone does not lead to the complete
reversal of HIF-mediated renoprotection. Indisputably
VEGF played significant roles in this disease model, yet
other factors induced by HIF must have contributed to
the histologic improvement.
Regarding specific properties of VEGF, there remains
a possibility that the induced VEGF prevented apop-
tosis of peritubular capillary endothelial cells, because
TUNEL-positive, apoptotic cells were observed not only
in tubular epithelium but also in the interstitial compart-
ment. Previous studies also suggested a role of VEGF as
a survival factor in tubular cells [45]. Another possibility
is left open that VEGF expression by this method fails to
protect renal vasculature in this model, but exerts angio-
genic properties in other disease models where hypoxia
takes part. Further work will be needed to completely
clarify this issue.
A second set of experiments were carried out to in-
vestigate whether cobalt administration exhibits syner-
gistic renoprotective effects with the ARB treatment in
the ischemic tubulointerstitium. Despite lots of exertions
to eradicate the progression of glomerular diseases, the
renoprotective role of any single regimen had been par-
tial, if any, and even the current gold standard therapy,
the blockade of RAS, has failed to halt the progression of
this disease model completely [46, 47]. Therefore, a new
antidote had been awaited that targets any aspect mod-
ulating the disease progression. And our new method
of activating HIF apparently served as an additive fac-
tor to protect the kidney from the ischemic insult. This
would signify a novel approach against progressive is-
chemic renal diseases and provide a rationale for devel-
oping new drugs that activate HIF, such as inhibitors of
prolyl hydroxylases.
The local action of Ang II can be either hemodynamic
or nonhemodynamic. On the one hand, it is known to
raise both systemic and glomerular/peritubular capillary
pressures, through disturbances of afferent and efferent
vascular tones [48, 49]. In the Thy1 nephritis model, it has
been established further that local Ang II promotes pro-
liferation of mesangial cells and stimulates the produc-
tion of proinflammatory and fibrogenic growth factors
[46, 50, 51] such as transforming growth factor-b (TGF-
b) and platelet-derived growth factor (PDGF), which in-
crease the production of extracellular matrix (ECM) and
retard the ECM degradation, thus accumulating the ECM
component in the affected tubulointerstitium. Tubules
surrounded by ECM proteins are exposed to further
impairment of tissue oxygenation and in turn will be a
secondary site of releasing inflammatory cytokines and
growth factors [4]. There is no known evidence, how-
ever, that TGF-b released by hypoxic tubular cells is
mediated by HIF-1. These molecular mechanisms would
also justify our therapeutic strategies to combine HIF-
activation with the RAS blockade. Once again, no data
have been available suggesting that the administration
of angiotensin-converting enzyme (ACE) inhibitors or
ARB alone can halt the disease progression completely
in the Thy1 model [46, 47] or in human nephropathies
[52]. These current limitations clearly highlight the sig-
nificance to seek for new antidotes that can be com-
bined with the RAS blockade and act through distinct
mechanisms.
The present study must be interpreted within the con-
text of certain limitations. First, we focused on only a few
of the HIF-regulated genes, so it cannot be concluded that
all genes activated by HIF are renoprotective. Indeed,
some are apparently positive factors, as in the case of
VEGF, EPO, and HO-1, but others may be at times detri-
mental. For example, a possibility has been suggested that
connective tissue growth factor (CTGF), a candidate me-
diator of tubulointerstitial fibrosis [53], is induced by hy-
poxia in a HIF-1–dependent manner [54]. Obviously, we
need to take both sides into consideration and details
downstream of HIF deserve further analysis. Second, the
administration period of cobalt was only 3 weeks, with
subsequent follow-up for up to 8 weeks, precluding the
feasibility of HIF-activation for longer periods of time.
Third, cobalt is toxic to the organic body. Although we
failed to observe toxic effects in terms of body weight, uri-
nary protein excretion, blood pressure and BUN levels,
it is obvious that cobalt per se cannot be applied in treat-
ing renal disorders. A new pharmacologic approach has
been awaited that successfully activates HIF with mini-
mal toxic effects.
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CONCLUSION
We demonstrated that cobalt administration activates
HIF-regulated genes and protects hypoxic tubulointersti-
tium from injury in the uninephrectomized Thy1 nephri-
tis model. Responsible mechanisms included inhibition
of tubular cell apoptosis and this strategy exhibited syn-
ergistic, renoprotective effects with the antiproteinuric
therapy. To our knowledge, this is the first study to ad-
dress the therapeutic, not preventive, approach against
chronic renal diseases. These findings imply that multi-
factorial mechanisms could be utilized as a valid target
for progressive renal diseases.
NOTE ADDED IN PROOF
After the manuscript was submitted for publication,
we uncovered the angiogenic properties of cobalt in the
rat remnant-kidney model, which we reported separately
(Tanaka T et al, Lab Invest 85:1292–1307, 2005).
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